Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $54.4 million.

  • Harvard Bioscience's Total Current Liabilities rose 13909.28% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.4 million, marking a year-over-year increase of 13909.28%. This contributed to the annual value of $55.0 million for FY2024, which is 10706.05% up from last year.
  • Per Harvard Bioscience's latest filing, its Total Current Liabilities stood at $54.4 million for Q3 2025, which was up 13909.28% from $55.2 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Total Current Liabilities ranged from a high of $55.6 million in Q1 2025 and a low of $20.7 million during Q1 2021
  • Its 5-year average for Total Current Liabilities is $30.3 million, with a median of $23.5 million in 2021.
  • In the last 5 years, Harvard Bioscience's Total Current Liabilities tumbled by 1472.49% in 2023 and then surged by 14402.99% in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's Total Current Liabilities stood at $25.3 million in 2021, then decreased by 8.16% to $23.2 million in 2022, then grew by 14.16% to $26.5 million in 2023, then surged by 107.06% to $55.0 million in 2024, then fell by 1.02% to $54.4 million in 2025.
  • Its last three reported values are $54.4 million in Q3 2025, $55.2 million for Q2 2025, and $55.6 million during Q1 2025.